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Abstract 
Background: Bone is a positive regulator of male fertility, which indicates a link between regulation 
of bone remodeling and reproduction or more specifically a link between calcium and androgens. This 
possibly suggests how calcium is linked to prostate cancer development through its link with the 
reproductive system. We studied serum calcium and sex steroid hormones in the Third National 
Health and Nutrition Examination Survey (NHANES III). 
Methods: Serum calcium and sex steroid hormones were measured for 1,262 men in NHANES III. 
We calculated multivariable-adjusted geometric means of serum concentrations of total and estimated 
free testosterone and estradiol, androstanediol glucuronide (AAG), and sex hormone binding globulin 
(SHBG) by categories of calcium (lowest 5% [<1.16 mmol/L], mid 90%, top 5% [e1.30 mmol/L]).  
Results: Levels of total and free testosterone, total estradiol, or AAG did not differ across categories 
of serum calcium. Adjusted SHBG concentrations were 36.4 for the bottom 5%, 34.2 for the mid 
90%, and 38.9 nmol/L for the top 5% of serum calcium (Ptrend=0.006), free estradiol levels were 0.88, 
0.92, and 0.80 pg/ml (Ptrend=0.048).  
Conclusions: This link between calcium and sex steroid hormones, in particular the U-shaped pattern 
with SHBG, may, in part, explain why observational studies have found a link between serum calcium 
and risk of prostate cancer.  
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Introduction 
Following positive findings for an association of intake of dairy products and calcium supplements 
with risk of prostate cancer (1-2), especially advanced disease, the link between serum levels of 
calcium and prostate cancer has been investigated lately (3-8). In the National Health and Nutrition 
Examination Survey I (NHANES I), comparing men in the top with men in the bottom tertile of 
serum calcium, the relative hazard was 2.68 (95% CI: 1.02-6.99) for fatal prostate cancer and 1.31 
(95% CI: 0.77-2.20) for incident prostate cancer for men in the highest tertile of serum calcium 
compared to the lowest (4). Moreover, a statistically significant correlation was found between serum 
calcium and free prostate-specific antigen (PSA) in NHANES 2005 to 2006, which indicates a 
possible link between the calcium metabolism and prostate cancer etiology (5).  
 
The link between calcium metabolism and PCa has also been found in pre-clinical studies. It was for 
instance shown in an athymic mouse model that tumour growth was effected by changes in dietary 
intake of vitamin D and calcium (9) . When trying to identify the 17alpha-hydroxylase/17,20 lyase 
inhibitor’s (VN/124-1) mechanism of action against androgen-dependent cancer models, it was shown 
that this drug affects intracellular calcium levels and as a consequence the release of calcium from the 
endoplasmic reticulum (10). This is again another illustration of a potential link between the calcium 
and androgen metabolism.   
 
Recently it was also shown that bone is a positive regulator of male fertility, which suggests a link 
between regulation of bone remodeling, energy metabolism, and reproduction or thus a link between 
the calcium and androgen metabolism (11). Since androgens promote cell proliferation and inhibit 
prostate cell death it is plausible that calcium is related to the risk of prostate cancer development via 
its link with the reproductive system (12-14). Androgens have been shown to modulate calcium 
through direct regulation of the STIM1 gene by androgen receptor binding to the STIM1 promoter 
(15). In relation to cancer, it has also been thought that there is a link between estrogen and calcium 
sensing receptor genotypes and serum calcium (16). The estrogen receptor-alpha, vitamin D receptor, 
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and the calcium-sensing receptor have been linked to carcinogenesis through their effects on calcium 
levels (16-17).  
 
In a cross-sectional analysis, we investigated serum calcium concentration in relation to 
concentrations of total testosterone, total estradiol, sex hormone-binding globulin (SHBG), 
androstanediol glucuronide (AAG), free testosterone, and free estradiol in adult males in the 
NHANES III, a nationally representative sample of non-institutionalized Americans. We 
hypothesized that men with higher serum calcium would have higher testosterone levels, lower 
estradiol, and higher SHBG.  
 
Methods 
Study population 
The National Center for Health Statistics (NCHS) conducted NHANES III between 1988 and 1994 
(18) and designed it as a multistage stratified, clustered probability sample of the US civilian non-
institutionalized population who was at least two months old. All subjects participated in an interview 
conducted at home and an extensive physical examination, which included a blood sample performed 
at a mobile examination center (18). NHANES III was conducted in two phases (1988-1991 and 
1991-1994) which both lead to independent unbiased national estimates of health and nutrition 
characteristics. Within each phase, subjects were randomly assigned to participate in either the 
morning or afternoon/evening examination session. Of the 2,205 men, who participated in the 
morning session of Phase I (1988-1991), we selected all men aged 20+ years who had serum 
measurements for total testosterone, total estradiol, SHBG, AAG, and calcium (n=1,262).  
 
Hormone measurements 
Stored serum samples were assayed for sex steroid hormones at the Children’s Hospital Boston, MA. 
Testosterone, estradiol, and SHBG concentrations were measured with competitive 
electrochemiluminescence immunoassays on the 2010 Elecsys autoanalyzer (Roche Diagnostics, 
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Indianapolis, IN) in 2005. AAG, an indicator of the conversion of testosterone to dihydrotestosterone, 
was measured with an enzyme immunoassay (Diagnostic Systems Laboratories, Webster, TX). 
Laboratory technicians were blinded to participant characteristics. The detection limits of the assays 
were 0.02 ng/ml, 5 pg/ml, 0.33 ng/ml, and 3 nmol/l for testosterone, estradiol, AAG, and SHBG, 
respectively. The coefficients of variation for quality control specimens were: testosterone 5.9% and 
5.8% at 2.5 and 5.5 ng/ml, respectively; estradiol 2.5%, 6.5%, and 6.7% at 39.4, 102.7 and 474.1 
pg/ml, respectively; AAG 9.5% and 5.0% at 2.9 and 10.1 ng/ml, respectively; and SHBG 5.3% and 
5.9% at 5.3 and 16.6 nmol/l, respectively. Quality control samples with a mean estradiol concentration 
of 39.4 pg/nL were also performed, which is then range of the of typical male estradiol concentrations 
(interassay coefficient of variantion: 2.5%)(19).  Free testosterone was estimated from total 
testosterone, SHBG, and albumin and free estradiol was estimated from total estradiol, SHBG and 
albumin using mass action equations (20-21).  
 
Exposure measurements 
Information on age, race/ethnicity, cigarette smoking, alcohol consumption, and physical activity was 
collected during the interview. Race and ethnicity were combined into four racial/ethnic groups: non-
Hispanic white, non-Hispanic black, Mexican American and other. Participants were classified as 
never, former, and current smokers (<20, 20-40, e40 cigarettes per day) based on the self-reported 
smoking habits. Frequency of alcohol consumption was measured by a food frequency questionnaire 
and categorized by times per week. Vigorous physical activity was defined by the following activities: 
jogging or running; swimming or aerobics (for men 40 years or older); biking, dancing, gardening, 
and calisthenics (for men 65 years or older); and walking and lifting weights (for men 80 years and 
older). Participants were defined as being diabetic when they reported a diagnosis of diabetes or when 
they were using insulin or diabetic medication. Percent body fat was estimated from anthropometric 
and bioelectrical impedance data using the equations of Chumlea and colleagues (22). Serum calcium 
was measured using a Hitachi 737 Analyzer (Boehringer Mannheim Diagnostics, Indianapolis, IN) 
(23-24). 25-hydroxy vitamin D was measured using the Diasorin radioimmunoassay kit (Diasorin, 
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Stillwater, MN, USA) on frozen serum from 1994 to 1995. Coefficients of variations from quality 
control samples ranged from 13% to 19%. The radioimmunoassay kit was calibrated using high-
performance liquid chromatographically purified vitamin D every six months. The protocols for the 
conduct of NHANES III were approved by the institutional review board of the NCHS, Centers for 
Disease Control and Prevention. Written informed consent was obtained from all participants. The 
Institutional Review Boards at the Johns Hopkins Bloomberg School of Public Health and the NCHS, 
Centers for Disease Control and Prevention approved the assay of stored serum specimens for the 
Hormone Demonstration Program. 
 
Statistical Analysis 
All analyses were conducted with Statistical Analysis Systems (SAS) release 9.2 (SAS Institute, Cary, 
NC) and SUDAAN 9.0 software (Research Triangle Park, NC) as implemented in SAS 9.2. Phase I 
morning sampling weights for NHANES III were used to account for sampling variability and to 
adjust for differential probability of selection of persons (18). First, we calculated the age-adjusted 
means or percentages of characteristics of the men by categories of serum calcium concentration by 
adjusting for the age distribution of the US population according to the 2000 Census. Since the 
calcium metabolism is tightly controlled, the following categories of calcium were chosen to capture 
extreme variation: the bottom 5%, mid 90%, and top 5%. Next, we calculated crude and adjusted 
geometric mean concentrations of the sex steroid hormones and their 95% confidence intervals (CI) 
by categories of serum calcium using linear regression. Hormone concentrations were not normally 
distributed, so we transformed them using the natural logarithm. The multivariable model was 
adjusted for age (continuous), race/ethnicity and factors that have been associated with hormone 
concentrations in previous NHANES III analyses: percent body fat, vigorous physical activity (yes or 
no), serum levels of vitamin D, cigarette smoking (never, former, current), alcohol intake (<2, 2-3, 4-6 
times a week, or daily or more), and history of diabetes. We also adjusted for serum levels of albumin 
to obtain an estimate of the free ionized calcium levels, which is the amount of metabolically active 
serum calcium (25). In a sensitivity analysis, we performed an additional adjustment for comorbidity 
as both sex steroid hormones and calcium may be associated with other comorbidities. The 
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comorbidity was evaluated with a comorbidity coefficient similar to the Charlson Comorbidity Index, 
as used in other NHANES III-based analyses (26). Each of the comorbidities available in the dataset 
contributed one point to the composite index with additional points given for older age. In addition, 
we performed stratified analyses for age groups (20-39, 40-59, e60 years), racial/ethnic groups, and 
serum levels of vitamin D (< / e  24.2 ng/mL) to determine whether the results were consistent 
between younger and older men, between different racial/ethnic groups, and between men with 
different vitamin D levels. Since older men, men of African descent, and men with lower vitamin D 
levels tend to have a higher risk of prostate cancer (27-28), it is possible that the association between 
calcium and sex-steroid hormones differs for these groups. Since vitamin D is regulated by calcium 
and has been shown to have antiproliferative effects on human prostate cancer cells (5, 29), the above 
analyses were also performed for serum calcium by low and high serum levels of vitamin D (30). We 
performed a test for interaction for all the above stratified analyses by introducing an interaction term 
in the linear regression models and testing its coefficient by the Wald test.  
 
Results 
Baseline characteristics of the study population by categories of serum calcium are shown in Table 1. 
The distribution of age, race/ethnicity, % body fat, and serum albumin generally did not differ 
statistically by categories of calcium. Those in the lowest 5% of serum calcium concentration had the 
largest proportion of current smokers (44.1%). Those in the highest 5% of serum calcium had the 
largest proportion of men who performed vigorous physical activity (18.1%). The mean level of 
vitamin D (26.3 ng/mL) was lowest for those in the bottom 5% of serum calcium. The mean level of 
albumin was slightly higher (43.7 g/L) in those in the top 5% of serum calcium. Finally, vitamin D 
concentration increased across and categories of serum calcium (P=0.038). 
 
When comparing the fully adjusted geometric means of the sex steroid hormones by categories of 
serum normalized calcium, levels of total and free testosterone, total estradiol, or AAG did not differ 
across categories of serum calcium. However, there was an upside down U-shaped association 
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between categories of serum calcium and free estradiol: 0.88 for the bottom 5% of serum calcium, 
0.92 in the middle 90%, and 0.80 pg/mL in the top 5% (Table 2). In addition, there was a U-shaped 
association for SHBG (P=0.006) (Table 2) across categories of serum calcium: 36.4 for the bottom 
5% of serum calcium, 34.2 in the middle 90%, and 38.9 nmol/mL for the top 5%. Additional 
adjustment for comorbidity did not alter the results dramatically (results not shown). 
 
Although age was not a statistically significant effect modifier, Table 3 shows that the above patterns 
for mean SHBG and free estradiol by serum calcium levels were only observed in men aged <40 (P-
trend=0.003 and 0.092, respectively).  
 
When stratifying by race/ethnicity, effect modification was observed for SHBG, total and free 
estradiol (Pinteraction=0.030, 0.005, and 0.003, respectively) (Table 4). Interestingly, the U-shaped 
pattern for SHBG was only observed for non-Hispanic white men, whereas an upside-down U-shaped 
pattern was observed among Mexican American men and a positive association was seen for non-
Hispanic black men (Table 4).  
 
No statistically significant effect modification was observed by median 25-hydroxy vitamin D levels, 
but the above observed U-shaped association for SHBG was only apparent for men with vitamin D 
levels e24.2 ng/mL, whereas the association for total estradiol was only apparent among those with 
vitamin D levels < 24.2 ng/mL. A sensitivity analysis including only non-Hispanic white men, did not 
alter these findings (results not shown).  
 
Serum calcium level modeled as a continuous measure was not statistically significantly associated 
with any of the hormones. 
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Discussion 
This cross-sectional study investigated how serum levels of calcium are correlated with levels of sex 
steroid hormones. We found that circulating calcium was especially associated with circulating levels 
of SHBG and free estradiol, but not total and free T, total E2, or AAG. This association was, in 
particular, observed in men aged 20 to 40 years and non-Hispanic white men. When stratified by 
levels of vitamin D, the U-shaped pattern for SHBG was only observed among men with 25-
hydroxyvitamin D levels e24.2 ng/mL, whereas the upside-down U-shaped pattern for free estradiol 
was only observed among men with 25-hydroxyvitamin D levels <24.2 ng/mL – however, the 
interaction was not statistically significant. 
 
Several observations and pathways suggest a link between serum calcium levels and sex steroid 
hormones (31-32): (1) both sex steroid hormones as well as serum calcium levels have been found 
predictive for the risk of prostate cancer development (27, 33); (2) sex steroid hormones and serum 
calcium levels have also been connected with bone health (Figure 1).  
 
Firstly, the link between sex steroid hormones and prostate cancer has been addressed in the context 
of androgen deprivation therapy and illustrated that the prostate is both an androgen-dependent and 
androgen-sensitive organ (34). Several epidemiological studies also assessed the link between serum 
levels of calcium and risk of prostate cancer (3-4, 6-7). Moreover, a study by Berry and colleagues 
showed that androgens modulate calcium through the direct regulation of the STIM1 gene by 
androgen receptor binding to the STIM1 promoter (15). However, currently no epidemiological study 
has examined whether an interaction in the association between circulating calcium levels and sex 
steroid hormone levels on the risk of prostate cancer incidence and progression may exist. Our data 
show an association between circulating levels of serum calcium and SHBG and free estradiol. Both 
sex steroid hormones have been found to be associated with severity and progression of prostate 
cancer (35-37). Using 18 prospective studies that included 3886 men with incident prostate cancer, 
the Endogenous Hormones and Prostate cancer Collaborative Group found an  inverse association 
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between serum concentration of SHBG prostate cancer risk (RR in the highest versus lowest fifth: 
0.86; 95% CI: 0.75-0.98)(38).  In the current study, the U-shaped association for SHBG was in 
particular observed for men aged 20 to 40 years and non-Hispanic white men, but there was also a 
statistically significant but different pattern in Mexican American men. This U-shaped pattern 
between levels of SHBG and serum calcium is also consistent with the U-shaped pattern for serum 
levels of calcium and risk of prostate cancer previously found (8). A modifying effect of 
race/ethnicity was also observed for the association between free estradiol and serum calcium. This is 
especially interesting since it has been previously shown that testosterone concentrations did not differ 
notably between black and white men in NHANES III (19). 
 
Another possible pathway between calcium and prostate cancer risk is via vitamin D, which is 
regulated by calcium and has been shown to have antiproliferative effects on human prostate cancer 
cells (5, 29). It has recently also been highlighted how calcium/calmodulin-dependent protein kinase 
kinase 2 (CAMKK2) is a key effector of the androgen receptor, regulating glycolytic flux by 
activating AMPK-PFK (5' AMP-activated protein kinase - phosphofructokinase) signaling, which in 
turn drives anabolism and thereby controls prostate cancer cell proliferation and tumour growth. 
CAMKK2 is thus regulated by the calcium/calmodulin complex and suggested to be an androgen 
receptor target in both androgen-dependent and castrate-resistant prostate cancer (32). Although there 
was no statistically significant interaction, the pattern for SHBG (i.e., low levels of SHBG with low 
and high calcium concentration and higher levels among men with calcium levels in the normal range) 
was only observed among men with 25-hydroxyvitamin D levels e24.2 ng/mL, whereas there was no 
association between circulating levels of SHBG and calcium in men with 25-hydroxyvitamin D levels 
<24.2 ng/mL. In contrast, the pattern for free estradiol (i.e., low free estradiol concentrations among 
men in the bottom and top categories of serum calcium) was only observed among men with 25-
hydroxyvitamin D levels <24.2 ng/mL.  
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Secondly, sex steroids have been found to influence bone mass in healthy men. Bone mineral density 
has been positively correlated with estradiol levels, whereas a inverse correlation was found with sex 
hormone-binding globulin, and no correlation was found with testosterone in men older than 65 years 
of age (31). It is also suggested that bone resorption is mainly regulated by estradiol, with a smaller 
but independent contribution of testosterone, whereas bone formation is regulated in equal proportions 
by the two hormones (31). Moreover, osteoporosis is a common side effect following androgen 
deprivation therapy for men with prostate cancer (39). It is observed that a rapid loss of bone-mineral 
density occurs within the first six to twelve months of endocrine treatment (40-42). A survival 
analysis based on the US SEER program, found that among men surviving at least five years after 
diagnosis, 19.4% of those who received androgen deprivation therapy had a fracture, as compared 
with 12.6% of those not receiving endocrine treatment (P<0.001)(43). It was recently shown in the 
Osteoporotic Fractures in Men Study that adverse skeletal effects of low sex steroid levels (SHBG, 
free testosterone and estradiol) were more pronounced in men with low vitamin D levels (44). 
Overall, our results showed an inverse association between circulating levels of free estradiol and 
calcium, but when stratified by levels of vitamin D this association was only apparent among men 
with low vitamin D levels. Nevertheless, it is also important to point out that free estradiol was 
calculated based on levels of SHBG, total estradiol, and albumin. Therefore, it is possible that the 
associations observed for free estradiol may follow from the patterns observed for SHBG. 
 
This study has several strengths including its generalizibility following the use of nationally 
representative data. Therefore it was also possible in our analysis to perform a stratified analysis by 
race/ethnicity. We were able to adjust for many potential confounding factors and examine effect 
modification by age, race/ethnicity, and vitamin D levels. A limitation of this study is that it relies on 
one single measurement so that it may be prone to measurement error and within-person variation. 
Moreover, our study used immunoassays instead of mass spectometry to evaluate serum levels of sex 
steroid hormones. Repeated measurements may strengthen the accuracy of the observed associations.  
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Conclusion 
The present results suggest that there may be a positive association between sex steroid hormones and 
serum levels of calcium. This link between calcium and sex steroid hormones, in particular SHBG, 
may explain why observational studies have found a link between serum calcium and risk of prostate 
cancer. The observed U-shaped pattern for SHBG and serum calcium was consistent with the U-
shaped pattern for serum calcium and prostate cancer risk found in other studies. A prospective study 
evaluating both serum levels of sex steroid hormones and calcium linked to risk and severity of 
prostate cancer or fractures could provide more insight into their roles related to prostate 
tumorigenesis and bone health.  
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Tables   
 Serum normalized total calcium (mmol/L) 
 Lowest 5% 
<1.16 
Mid 90% 
1.16-1.30 
Top 5% 
e1.30 
n 47 1137 78 
Age (years)    
Mean (SE) 45.19 (0.83) 45.69 (0.25) 46.14 (1.11) 
Race - Ethnicity (%)    
Non-Hispanic white 78.80 78.01 72.72 
Non-Hispanic black 10.31 9.01 18.61 
Mexican-American 5.82 4.54 5.93 
Other  5.07 8.44 2.74 
Percent Body fat (%)    
Mean (SE) 25.21 (1.50) 25.27 (0.25) 25.29 (0.62) 
Cigarette smoking (%)     
Never 29.52 34.98 53.81 
Former 26.36 31.81 17.78 
Current (<20 cigarettes/day) 32.91 22.08 25.01 
Current (20-40 cigarettes/day) 0.94 7.16 0.00 
Current (e  40 cigarettes/day) 10.26 3.98 3.41 
Alcohol intake (%)    
Up to once a week 53.87 47.29 52.57 
2-3 times a week 0.00 18.14 19.46 
4-6 times a week 28.54 17.23 12.89 
Daily or more 17.58 17.34 15.08 
Vigorous Physical activity (%) 12.49 13.59 18.11 
Diabetes (%) 9.26 3.74 3.10 
Calcium (mmol/L)    
Mean (SE) 1.13 (0.004) 1.23 (0.002) 1.32 (0.004) 
Vitamin D (ng/mL)     
Mean (SE) 26.32 (2.17) 31.04 (0.69) 32.93 (1.45) 
Albumin (g/L)    
Mean (SE) 42.75 (0.86) 43.22 (0.16) 43.74 (0.39) 
Table 1 Age-adjusted (standardized to the 2000 US Census age distribution) weighted characteristics 
by quintiles of serum calcium, men, NHANES III 1988-1991. 
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 Geometric mean (95% confidence interval) of serum 
normalized calcium (mmol/L)  
P for trend P for T-test 
between 
lowest and 
top 5% 
 Lowest 5% 
<1.16 
Mid 90% 
1.16-1.30 
Top 5% 
e1.30 
  
Age and Race Adjusted Model      
Total testosterone (ng/ml) 4.86 (4.16-5.67) 4.98 (4.81-5.16) 5.30 (4.98-5.65) 0.031 0.010 
Total estradiol (pg/ml) 36.86 (33.25-40.87) 35.95 (34.39-37.57) 32.41 (29.11-36.09) 0.197 0.302 
SHBG (nmol/l) 35.60 (32.23-40.58) 34.39 (32.93-35.92) 39.89 (35.62-44.67) 0.011 0.383 
Androstanediol glucuronide (ng/ml) 13.08 (9.64-17.74) 11.62 (11.04-12.23) 11.42 (9.98-13.05) 0.488 0.245 
Free testosterone (ng/ml) 0.095 (0.085-0.107) 0.099 (0.096-0.103) 0.098 (0.090-0.106) 0.363 0.023 
Free estradiol (pg/ml) 0.944 (0.866-1.029) 0.920 (0.875-0.968) 0.789 (0.699-0.891) 0.082 0.259 
25-hydroxy Vitamin D (ng/mL) 23.27 (18.12-29.89) 29.12 (27.78-30.51) 31.85 (29.33-34.57) 0.072 0.050 
Fully Adjusted Model      
Total testosterone (ng/ml) 4.75 (4.15-5.43) 4.98 (4.85-5.12) 5.20 (4.81-5.62) 0.441 0.551 
Total estradiol (pg/ml) 35.03 (30.83-39.80) 36.01 (34.60-37.47) 32.23 (29.18-35.59) 0.158 0.163 
SHBG (nmol/l) 36.36 (32.78-40.33) 34.16 (32.87-35.51) 38.94 (35.79-42.38) 0.006 0.212 
Androstanediol glucuronide (ng/ml) 13.46 (10.28-17.63) 11.68 (11.05-12.35) 11.91 (10.15-13.98) 0.592 0.580 
Free testosterone (ng/ml) 0.091 (0.080-0.103) 0.100 (0.097-0.103) 0.098 (0.089-0.108) 0.341 0.145 
Free estradiol (pg/ml) 0.883 (0.783-0.995) 0.923 (0.883-0.965) 0.797 (0.717-0.887) 0.048 0.379 
25-hydroxy Vitamin D (ng/mL) 23.52 (18.43-30.01) 29.16 (27.92-30.46) 32.40 (29.94-35.07) 0.038 0.045 
Table 2 Geometric mean (95% CI) of sex steroid hormone concentrations by extreme measures of 
calcium in a nationally representative sample of adult men in NHANES III. All adjusted means take 
into account age, race/ethnicity, %body fat, diabetes, cigarette smoking, alcohol intake, vigorous 
physical activity, and serum levels of vitamin D and albumin.  
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 Geometric mean (95% confidence interval) of serum normalized 
calcium (mmol/L) 
P for trend P for Interaction 
 Lowest 5% 
<1.16 
Mid 90% 
1.16-1.30 
Top 5% 
e1.30 
  
Age 20-39      
Total testosterone (ng/ml) 5.64 (4.68-6.80) 5.71 (5.50-5.92) 6.27 (5.59-7.03) 0.292  
Total estradiol (pg/ml) 33.50 (26.32-42.63) 37.86 (36.55-39.22) 35.30 (31.08-40.09) 0.351  
SHBG (nmol/l) 36.00 (31.25-41.46) 30.01 (28.40-31.70) 36.13 (31.02-42.09) 0.003  
Androstanediol glucuronide (ng/ml) 14.94 (10.08-22.16) 12.98 (12.28-13.75) 13.60 (11.24-16.45) 0.726  
Free testosterone (ng/ml) 0.110 (0.092-0.131) 0.124 (0.120-0.128) 0.124 (0.111-0.138) 0.432  
Free estradiol (pg/ml) 0.833 (0.665-1.042) 0.990 (0.950-1.032) 0.874 (0.761-1.005) 0.092  
Vitamin D (ng/mL) 26.63 (21.85-32.47) 30.52 (28.67-32.50) 34.64 (29.65-40.47) 0.151  
Age 40-59      
Total testosterone (ng/ml) 4.22 (3.37-5.28) 4.61 (4.33-4.90) 4.59 (3.62-5.81) 0.793 0.564 
Total estradiol (pg/ml) 34.81 (29.65-40.88) 34.69 (33.04-36.42) 29.09 (24.47-34.57) 0.195 0.586 
SHBG (nmol/l) 33.31 (27.98-39.66) 35.05 (33.30-36.89) 37.51 (33.30-42.26) 0.447 0.398 
Androstanediol glucuronide (ng/ml) 11.20 (7.67-16.36) 11.14 (10.25-12.10) 11.92 (7.18-19.79) 0.968 0.925 
Free testosterone (ng/ml) 0.084 (0.068-0.104) 0.091 (0.085-0.097) 0.088 (0.067-0.117) 0.785 0.919 
Free estradiol (pg/ml) 0.911 (0.767-1.083) 0.896 (0.851-0.943) 0.745 (0.617-0.117) 0.223 0.505 
Vitamin D (ng/mL) 19.73 (13.18-29.54) 28.04 (26.87-29.25) 30.85 (23.73-40.05) 0.219 0.085 
Age e60      
Total testosterone (ng/ml) 3.53 (2.86-4.36) 3.88 (3.56-4.22) 3.87 (2.75-5.43) 0.675  
Total estradiol (pg/ml) 33.66 (27.91-40.60) 33.45 (31.76-35.23) 29.19 (21.28-40.02) 0.671  
SHBG (nmol/l) 46.03 (40.19-52.72) 47.89 (45.81-50.06) 50.22 (36.27-69.55) 0.838  
Androstanediol glucuronide (ng/ml) 12.37 (6.75-22.69) 9.36 (8.62-10.17) 8.45 (5.55-12.87) 0.577  
Free testosterone (ng/ml) 0.057 (0.045-0.072) 0.062 (0.057-0.068) 0.059 (0.041-0.086) 0.744  
Free estradiol (pg/ml) 0.815 (0.690-0.964) 0.795 (0.753-0.840) 0.675 (0.493-0.923) 0.584  
Vitamin D (ng/mL) 25.87 (21.06-31.78) 27.66 (26.27-29.11) 24.57 (21.57-27.98) 0.228  
Table 3 Age-stratified geometric mean (95% CI) of sex steroid hormone concentrations by extreme 
measures of calcium in a nationally representative sample of adult men in NHANES III. All models 
are adjusted for age, race/ethnicity, %body fat, diabetes, cigarette smoking, alcohol intake, vigorous 
physical activity, and serum levels of vitamin D and albumin.  
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 Geometric mean (95% confidence interval) of serum normalized 
calcium (mmol/L) 
P for trend P for 
Interaction 
 Lowest 5% 
<1.16 
Mid 90% 
1.16-1.30 
Top 5% 
e1.30 
  
Non-Hispanic white      
Total testosterone (ng/ml) 4.88 (4.17-5.71) 5.04 (4.85-5.23) 5.35 (4.76-6.00) 0.475  
Total estradiol (pg/ml) 35.14 (29.94-41.25) 35.57 (34.00-37.21) 32.43 (28.97-36.30) 0.402  
SHBG (nmol/l) 36.90 (32.11-42.40) 34.61 (33.17-36.11) 40.78 (36.31-45.81) 0.010  
Androstanediol glucuronide (ng/ml) 14.49 (10.66-19.71) 12.29 (11.49-13.15) 11.98 (9.96-14.40) 0.568  
Free testosterone (ng/ml) 0.093 (0.080-0.109) 0.100 (0.096-0.104) 0.098 (0.086-0.111) 0.638  
Free estradiol (pg/ml) 0.884 (0.763-1.024) 0.906 (0.862-0.952) 0.791 (0.699-0.894) 0.165  
Vitamin D (ng/mL) 24.53 (18.73-32.13) 31.57 (30.08-33.13) 34.97 (31.37-38.99) 0.057  
Non-Hispanic black      
Total testosterone (ng/ml) 3.93 (2.95-5.23) 5.49 (5.17-5.84) 5.46 (4.04-7.36) 0.034 0.091 
Total estradiol (pg/ml) 34.24 (30.98-37.85) 42.94 (41.41-44.52) 35.13 (31.00-39.80) <0.001 0.005 
SHBG (nmol/l) 34.43 (26.74-44.32) 35.10 (34.00-36.86) 40.69 (33.68-49.15) 0.431 0.030 
Androstanediol glucuronide (ng/ml) 10.73 (7.92-14.54) 10.50 (9.72-11.35) 13.27 (9.33-18.87) 0.496 0.655 
Free testosterone (ng/ml) 0.072 (0.051-0.097) 0.111 (0.104-0.118) 0.103 (0.074-0.143) 0.010 0.384 
Free estradiol (pg/ml) 0.864 (0.761-0.981) 1.110 (1.069-1.153) 0.872 (0.768-0.990) <0.001 0.003 
Vitamin D (ng/mL) 16.00 (9.48-27.00) 20.19 (18.10-22.53) 19.74 (17.20-22.65) 0.512 0.653 
Mexican American      
Total testosterone (ng/ml) 4.74 (3.76-5.98) 5.17 (5.02-5.32) 4.79 (4.29-5.35) 0.300  
Total estradiol (pg/ml) 37.35 (30.75-45.38) 33.46 (32.20-34.76) 34.92 (31.73-38.45) 0.309  
SHBG (nmol/l) 26.67 (22.75-33.66) 31.12 (29.99-32.28) 25.25 (22.31-28.58) 0.004  
Androstanediol glucuronide (ng/ml) 12.74  (9.46-17.14) 11.53 (10.81-12.30) 10.50 (7.07-15.57) 0.601  
Free testosterone (ng/ml) 0.106 (0.086-0.132) 0.110 (0.106-0.113) 0.112 (0.097-0.129) 0.932  
Free estradiol (pg/ml) 1.019 (0.848-1.224) 0.881 (0.847-0.916) 0.968 (0.877-1.069) 0.023  
Vitamin D (ng/mL) 22.32 (17.77-28.04) 25.21 (24.62-25.82) 27.12 (24.72-29.76) 0.278  
Table 4 Race/ethnicity-stratified geometric mean (95% CI) of sex steroid hormone concentrations by 
by extreme measures of calcium in a nationally representative sample of adult men in NHANES III. 
All models are adjusted for age, race/ethnicity, %body fat, diabetes, cigarette smoking, alcohol intake, 
vigorous physical activity, and serum levels of vitamin D and albumin.  
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 Geometric mean (95%Confidence Interval) of serum normalized 
Calcium (mmol/L) 
P for trend P for 
interaction 
 Lowest 5% 
<1.16 
Mid 90% 
1.16-1.30 
Top 5% 
e1.30 
  
Vitamin D < 24.2 ng/mL      
Total testosterone (ng/ml) 3.60 (3.00-4.31) 4.51 (4.24-4.80) 5.21 (4.43-6.13) 0.015 0.136 
Total estradiol (pg/ml) 32.91 (29.64-36.55) 36.72 (35.21-38.29) 31.03 (28.71-33.54) 0.005 0.145 
SHBG (nmol/l) 31.91 (29.17-34.90) 32.54 (31.47-33.64) 36.26 (30.60-42.96) 0.361 0.873 
Androstanediol glucuronide (ng/ml) 10.65 (9.26-12.26) 10.97 (9.98-12.06) 11.53 (9.02-14.74) 0.834 0.468 
Free testosterone (ng/ml) 0.072 (0.059-0.087) 0.092 (0.087-0.098) 0.103 (0.083-0.128) 0.022 0.232 
Free estradiol (pg/ml) 0.864 (0.779-0.957) 0.959 (0.921-0.999) 0.792 (0.724-0.868) 0.004 0.135 
Vitamin D e  24.2 ng/mL      
Total testosterone (ng/ml) 5.25 (4.55-6.07) 5.21 (5.08-5.35) 5.21 (4.79-5.67) 0.993  
Total estradiol (pg/ml) 36.76 (31.65-42.70) 35.68 (34.08-37.35) 32.71 (29.29-36.53) 0.325  
SHBG (nmol/l) 38.52 (33.31-44.54) 34.94 (33.04-36.95) 39.56 (34.97-44.74) 0.05  
Androstanediol glucuronide (ng/ml) 14.92 (10.41-21.39) 12.01 (11.28-12.79) 12.26 (10.50-14.32) 0.516  
Free testosterone (ng/ml) 0.098 (0.087-0.112) 0.103 (0.100-0.107) 0.096 (0.088-0.105) 0.323  
Free estradiol (pg/ml) 0.910 (0.791-1.045) 0.907 (0.859-0.957) 0.801 (0.708-0.907) 0.177  
Table 5 Vitamin D (median) -stratified geometric mean (95% CI) of sex steroid hormone 
concentrations by extreme measures of calcium in a nationally representative sample of adult men in 
NHANES III. All models are adjusted for age, race/ethnicity, %body fat, diabetes, cigarette smoking, 
alcohol intake, vigorous physical activity, and serum levels of vitamin D and albumin.  
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Figure 1 Potential pathways between serum calcium and sex steroid hormones. 
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